Patent Issued for Allos Therapeutics’ Cancer Drug Folotyn

Colorado biotech firm Allos Therapeutics Inc. said Monday that a patent has been issued for the use of its key product, the cancer drug Folotyn, to treat T-cell lymphoma.
Denver Business Journal